about our science

Traditional interventions for infectious diseases are centered on the development of vaccines and anti-infectives for prevention and treatment. These approaches have focused a single treatment on a single pathogen (“one drug, one bug”), with diminshing efficacy over time due to the emergence of resistance.

Pulmatrix believes it has uncovered a novel approach that will transform the landscape of infectious and progressive respiratory diseases with multi-faceted product offerings that will uniquely treat and control respiratory disease. Pulmatrix’s innovative technology is pathogen independent and reduces chronic airway inflammation so it has potential to prevent and treat a range of respiratory infections including influenza and acute exacerbations of chronic respiratory diseases such as COPD, asthma and CF.

Pulmatrix’s drugs are uniquely able to deliver these benefits via a dual mechanism of action that enhances and stimulates the inherent biophysical and biochemical properties of the airway:

biological:

iCALM therapy stimulates host defense mechanisms in the lung that prevent infection, enhance the clearance of pathogens, and reduce airway inflammation.

biophysical:

In the airway lining fluid (ALF), iCALM therapies activate the assembly of endogenous proteins into three dimensional matrices, resulting in enhanced barrier function in the lung and reducing the penetration of pathogens into the lung tissue. These changes in the rheological properties of the airway further lead to a reduction in the formation and exhalation of infectious bioaerosols.

This unique approach of enhancing and harnessing the biophysical capabilities of the airway while augmenting host defense mechanisms offers a novel approach to treat, prevent, and help control infectious and progressive respiratory disease.